UT partners with industry to commercialize the discoveries in our labs and bring biologic therapies and innovations to the patient. In the past 10 years, our Discovery to Impact team has executed over 705 option and license agreements.
-
Aeglea BioTherapeutics is a clinical-stage company developing human enzyme therapies for rare metabolic diseases like Arginase 1 Deficiency and Homocystinuria. The company was formed to build a platform of novel human enzyme therapeutics, initially using molecules from UT.
-
Icosavax is advancing vaccines against severe life-threatening illnesses, including a candidate for human metapneumovirus (hMPV) using technology from UT.
-
Vaxxas is commercializing novel vaccination technology that employs a proprietary microprojection patch for delivery to the skin. The company has obtained a license to use the SARS-CoV-2 spike subunit antigen, HexaPro, from UT to enable development of a patch-based vaccine for SARS-CoV-2.
Commercialization News
Research Identifies Key Antibodies for Development of Broadly Protective Norovirus Vaccine
Discovery brings us one step closer to vaccine and treatment for prevalent virus.
Businesswire
Vaxxas Licenses HexaPro Spike Glycoprotein from University of Texas at Austin for Use on its Needle-Free Vaccine Patches
The University of Texas at Austin has granted Vaxxas an exclusive license to a next-generation SARS-CoV-2 spike subunit vaccine (HexaPro).
Department of Molecular Biosciences
New Vaccine Advances Could Help Against More Viral Illnesses
Jason McLellan and his team advance understanding of human metapneumovirus (hMPV) and human cytomegalovirus (HCMV), which can help them develop vaccines.
